car t cell podcasts

As boas notícias da ciência no combate ao câncer

Play Episode Listen Later Jun 15, 2026 29:36

Convidados: Fernando Maluf, médico oncologista e cofundador do Instituto Vencer o Câncer, e Diego Villa Clé, professor doutor de Hematologia da USP e coordenador de Biotecnologia e do Núcleo de Terapias Avançadas do Hemocentro de Ribeirão Preto. No início de junho, mais de 50 mil médicos e pesquisadores se reuniram no maior congresso de oncologia do mundo, realizado em Chicago (EUA). Juntos, eles aplaudiram de pé – até emocionados e com lágrimas nos olhos – o resultado de um estudo clínico. A cena, que é incomum em eventos científicos como esse, foi uma celebração do resultado da daraxonrasib, uma pílula que dobrou a sobrevida de pacientes com câncer de pâncreas, considerado o tipo de câncer mais letal pelos médicos. Na última semana, a boa notícia veio de Ribeirão Preto: pesquisadores da USP anunciaram que a terapia CAR-T Cell, que modifica as células do sistema imunológico, apresentou quase 90% de eficácia em pacientes com linfoma, um tipo de câncer no sangue. A tecnologia foi totalmente desenvolvida no Brasil, e o ministro da Saúde, Alexandre Padilha, afirmou que pretende incorporar o tratamento ao SUS. Neste episódio, Natuza Nery entrevista dois médicos. Primeiro, ela conversa com o oncologista Fernando Maluf, que explica o funcionamento da daraxonrasib e conta o que há de mais moderno no tratamento contra o câncer. Depois, quem participa é Diego Villa Clé, coordenador da pesquisa que desenvolveu a terapia CAR-T Cell na USP-Ribeirão Preto. Também neste episódio, Paulo Peregrino, um dos pacientes deste tratamento experimental, relata parte do processo de remissão de seu câncer.

brasil neste depois sus tamb juntos primeiro usp combate boas cias preto ribeir biotecnologia car t cell alexandre padilha hematologia natuza nery

Legend Biotech's CAR T-Cell Breakthrough: 100% Response Rate | Pharma and Biotech Daily

Pharma and BioTech Daily

Play Episode Listen Later Jun 4, 2026 5:50

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most significant advancements in scientific research, clinical trials, and regulatory landscapes within the industry. These developments are shaping the future of patient care and drug development significantly. Starting with Legend Biotech's LB2501, which achieved an impressive 100% response rate in a Phase 1 study for non-Hodgkin lymphoma using in vivo CAR T-cell therapy. This breakthrough highlights the transformative potential of CAR T-cell therapies in oncology, especially for B-cell lymphomas. Such success opens the door for accelerated regulatory pathways, offering hope to patients with limited treatment options. In another key development, JJP Biologics shared positive interim data from its Phase 1b trial of nebaprubart targeting CD89 in linear IgA disease. This monoclonal antibody is promising in treating autoimmune conditions by targeting specific disease mechanisms. Meanwhile, GSK's Velzatinib (IDRX-42) achieved a 61% response rate in Phase 1/1b trials for gastrointestinal stromal tumors, showing efficacy against cases resistant to treatments like imatinib. Johnson & Johnson's Nipocalimab met its primary endpoint in a Phase 2 study for systemic lupus erythematosus, underscoring the potential of FcRn blockade in managing autoimmune diseases. Zenas Biopharma's Phase 3 data for Obexelimab targeting CD19/FcγRIIB in IgG4-related disease further emphasizes the role of targeted therapies in managing complex autoimmune disorders. On the regulatory front, Foundation Medicine's FoundationOne Blood Test received FDA approval as a companion diagnostic for Pfizer's Talzenna (talazoparib) to treat prostate cancer with homologous recombination repair gene mutations. This approval underscores the growing importance of precision medicine and companion diagnostics in tailoring cancer treatments based on genetic profiles. Additionally, Lupin and Natco Pharma secured FDA approval for their generic version of Eribulin Mesylate Injection, essential for reducing healthcare costs and improving patient access to vital therapies. Eli Lilly's collaboration with Ascidian Therapeutics focuses on RNA exon editing for kidney diseases, potentially revolutionizing treatment approaches by correcting genetic errors at the RNA level. This partnership reflects a burgeoning interest in RNA-based therapies and their capacity to address unmet medical needs. Regeneron expanded its pact with CytomX Therapeutics to develop conditionally active bispecific antibodies, emphasizing innovation in oncology drug discovery. Such collaborations combine expertise across companies to expedite cutting-edge therapies' development. In terms of funding, NewLimit's successful $435 million Series C round aims to advance epigenetic reprogramming medicine towards human trials. This initiative highlights the burgeoning field of aging biology and its implications for extending healthy human lifespan through innovative therapeutic approaches. Similarly, Immu Biosciences raised $53 million to enhance its immunology platform using AI/ML technologies, underscoring AI and machine learning's critical role in accelerating drug development processes. Turning our gaze towards China's expanding influence on the global biotech stage, Akeso's presentation at ASCO 2026 marked a significant milestone as it became the first-ever Chinese dataset featured in a plenary session. This achievement underscores China's growing prominence in biotechnology and highlights its commitment to advancing innovative medical solutions globally. Simultaneously, Gilead's strategic partnership with Cencora aims to enhance access to CAR-T therapies like Yescarta and Tecartus by expanding their network of treatment centers. CAR-T therapies represent a paradigm shift in cancer treatment by offering personalized options for certain types of cancer. Despite challenges such as Roche's setbacks with its oral SERD drug giredestrant in breast cancer trials, innovation continues unabated. Zevra Therapeutics' launch of Miplyffa for Niemann-Pick disease type C exemplifies efforts to transform rare disease markets by improving patient outcomes through increased access and tailored treatment strategies. Finally, Eli Lilly's acquisition spree reflects broader trends where pharmaceutical companies increasingly integrate Chinese innovations into their development pipelines. This period marks a transformative phase characterized by collaboration between global pharma giants and Chinese biotechs, signaling an era where innovation is globalized and aimed at addressing critical healthcare challenges worldwide. These advancements reflect a dynamic period of innovation within the pharmaceutical and biotech industries. The focus on personalized medicine, targeted therapies, and groundbreaking technologies like RNA editing indicates a shift towards more precise treatment modalities. As these discoveries transition from research phases to clinical applications, they hold the potential to transform patient care significantly. Strategic partnerships and substantial funding initiatives illustrate a robust ecosystem supporting these innovations' rapid advancement. As regulatory bodies continue approving novel therapeutics and diagnostics, the emphasis on personalized healthcare will likely drive future developments, ultimately leading to improved patient outcomes worldwide. As we continue navigating these developments, it's clear that the pharmaceutical and biotech sectors are on the cusp of transformative breakthroughs that promise to redefine healthcare delivery across multiple domains. Thank you for tuning into Pharma Daily; stay informed and stay ahead.Support the show

Podcast: Exploring and Managing Gastrointestinal-Related CAR T-Cell Lymphomas

ASTCT Talks

Play Episode Listen Later Jun 2, 2026 19:57

In a special cobranded episode between Oncology on the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, host Rahul Banerjee, MD, FACP, spoke with colleague Hitomi Hosoya, MD, PhD, about a study she and coauthors published in Blood. In their study, Hosoya and colleagues assessed the underlying mechanisms of chimeric antigen receptor (CAR) T-cell–related lymphomas developing in the gastrointestinal (GI) tract. The study focused on a particular case involving a 50-year-old patient with relapsed/refractory multiple myeloma who developed T-cell lymphoma after receiving cellular therapy in the seventh-line setting. Listen below or via your favorite podcast platform.

phd blood managing md gi cart american society oncology lymphoma transplantation gastrointestinal car t cell rahul banerjee

S1 Ep211: Exploring and Managing Gastrointestinal-Related CAR T-Cell Lymphomas

Oncology Peer Review On-The-Go

Play Episode Listen Later Apr 27, 2026 19:57

In a special cobranded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, host Rahul Banerjee, MD, FACP, spoke with colleague Hitomi Hosoya, MD, PhD, about a study she and coauthors published in Blood. In their study, Hosoya and colleagues assessed the underlying mechanisms of CAR T-cell–related lymphomas developing in the gastrointestinal tract. The study focused on a particular case involving a 50-year-old patient with relapsed/refractory multiple myeloma who developed T-cell lymphoma after receiving cellular therapy in the seventh-line setting. The discussion began with an overview of the patient's treatment course, who initially responded well to seventh-line CAR T-cell therapy and experienced grade 1 cytokine release syndrome with no neurotoxicity. Two months after initiating this line of therapy, the patient experienced diarrhea and subsequent hospitalization. Following multiple endoscopies and the use of steroids and other biologic agents, the patient's diarrhea persisted, which resulted in notable weight loss and cachexia. A biopsy revealed that the patient had developed T cell infiltration in the small intestine, which correlated with an eventual diagnosis of T-cell lymphoma. After the patient's diagnosis, Hosoya outlined her team's decision to administer cyclosporine to help mitigate and eventually resolve the patient's diarrhea. Beyond this symptom management, she highlighted the challenges of treating those with GI-related T-cell lymphomas based on a lack of sufficient treatment protocols and clinical experience across the country. Overall, she emphasized teamwork as an essential component of managing and further understanding CAR T-cell lymphomagenesis.Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center and a member of the ASTCT Content Committee. Hosoya is a principal investigator in Hematology & Cellular Therapy at Cedars-Sinai Medical Center and an instructor of Blood and Marrow Transplant and Cellular Therapy at Stanford University.ReferenceHosoya H, Bastidas Torres AN, Fernandez-Pol S, et al. Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine. Blood. 2026;147(11):1191-1198. doi:10.1182/blood.2025031423

phd blood managing md stanford university gi cart american society lymphoma transplantation gastrointestinal banerjee hematology cedars sinai medical center car t cell cellular therapy clinical research division rahul banerjee

Real-world availability of CAR T-cell therapies

Blood Podcast

Play Episode Listen Later Apr 16, 2026 9:58

In this week's episode, Blood podcast editor Laurie Sehn interviews Drs. Edward Cliff on his latest research published in volume 147 issue 14 of Blood. Dr. Cliff discusses "Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries" which maps the mismatch between innovation and implementation across high-income and selected-upper-middle-income countries for US Food and Drug Administration–approved products and indications.

blood global medical real world cliff drs cart g20 availability oncology leukemia therapies drug administration lymphoma medical research hematology us food car t cell

S16 Ep34: Utilizing Real-World Analyses Help Make Sense of Multiple Approved CAR T-Cell Therapies for ALL: With Jae Park, MD

OncLive® On Air

Play Episode Listen Later Mar 25, 2026 9:55

In today's episode, Jae Park, MD, discussed all things CAR T-cell therapy in acute lymphoblastic leukemia (ALL), touching on topics like where this treatment modality fits into the ALL paradigm, how it affects clinical practice, and how to go about selecting between the multiple FDA-approved options. Dr Park is the chief of the Cellular Therapy Service at Memorial Sloan Kettering Cancer Center in New York, New York. In our exclusive interview, Dr Park began with a conversation about the November 2024 FDA approval of obecabtagene autoleucel (obe-cel; Aucatzyl) and the October 2021 FDA approval of brexucabtagene autoleucel (brexu-cel; Tecartus) for patients with ALL. He explained how these CAR T-cell therapies fit into the ALL treatment paradigm for patients who have relapsed disease. After weighing how the safety and efficacy of each therapy stack up against others, Dr Park then discussed analyses that have come out after the obe-cel approval and their effect on obe-cel usage. Dr Park pointed out real-world studies presented at the 2025 ASH Annual Meeting, as well as analyses of the phase 1/2 FELIX trial (NCT04404660), which supported the approval of obe-cel. Finally, Dr Park looked ahead to the future of CAR T-cell therapies for ALL, noted in which settings he believes this class of agents will see the most use, and explained how to make treatment selections between therapies like brexu-cel and obe-cel.

new york park md fda real world utilizing make sense cart approved therapies analyses memorial sloan kettering cancer center help make car t cell ash annual meeting

Episode 407: Pharmacology 101: CAR T-Cell Immunotherapy

The Oncology Nursing Podcast

Play Episode Listen Later Mar 20, 2026 48:31

"You want to try to act quickly and be able to know what the pathways are for appropriate escalating when a patient is having symptoms that are reflective of cytokine release syndrome (CRS) or neurotoxicity. These toxicities are very manageable and treatable when recognized early. To summarize, choosing the right patient, knowing the toxicity profile for each product, and acting early is really what helps to prevent severe outcomes with chimeric antigen receptor (CAR) T-cell therapy," Maribel Pereiras, PharmD, BCPS, BCOP, clinical pharmacy specialist at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about CAR T-cell immunotherapy. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by March 20, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to CAR T-Cell immunotherapy in the treatment of cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 267: Side-Effect Management for CAR T-Cell Therapy for Hematologic Malignancies Episode 261: CAR T-Cell Therapy for Hematologic Malignancies Requires Education and Navigation Episode 176: Oncologic Emergencies 101: Cytokine Release Syndrome ONS Voice articles: A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities CAR T-Cell Therapy Programs Oncology Clinical Social Workers Add Layers of Support for Patients and Families During CAR T-Cell Therapy Studies Show Best Practices to Manage CAR T-Cell Therapies' irAEs and Improve Outcomes ONS Voice oncology drug reference sheet: Lisocabtagene Maraleucel Clinical Journal of Oncology Nursing articles: CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma CAR T-Cell Therapy: Updates in Nursing Management Nursing Considerations in Navigating Patients Receiving CAR T-Cell Therapy ONS book: Guide to Cancer Immunotherapy (second edition) ONS Huddle Cards: Chimeric Antigen Receptor T-Cell Therapy Cytokine Release Syndrome Immune Effector Cell–Associated Neurotoxicity Syndrome Immunotherapy Immuno-Oncology Learning Library American Society of Gene and Cell Therapy: Learning Center American Society for Transplantation and Cellular Therapy: Learning Center National Comprehensive Cancer Network home page To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "CAR T-cell therapy combines an adoptive cell transfer with genetic engineering. And what that really means is that we are harvesting a patient's own T cells and then we engineer them with a synthetic receptor that helps them recognize that cancer. And all of this work has evolved through many decades of stepwise advances in how we design and activate the T cells. That led us to several landmark trials and ultimately the first CAR T-cell therapy approved by the U.S. Food and Drug Administration in 2017, which was tisagenlecleucel for pediatric and young adult patients that had acute lymphoblastic leukemia." TS 3:34 "If a patient has higher disease burden or an inflammatory biology, that does tend to correlate with higher toxicity risk. And then that might influence the way we monitor the patients who are getting the CAR T therapy. And then finally, baseline neurologic examinations, because neurotoxicity can occur with these agents. It's very important that we as a whole healthcare team really understand what the patient looks like at baseline to be able to determine if they're having any altered changes or confusion. If I had to summarize it, we want to confirm the target and make sure that we have the right CAR T product for the patient. We want to confirm that the patient, physiologically and mentally, is ready for the CAR T therapy." TS 10:53 "I think the two [toxicities] that every nurse will hear about almost immediately when talking about CAR T therapy are CRS or ICANS, which stands for immune effector cell–associated neurotoxicity syndrome. ... ICANS can either follow or even occur alongside CRS. And this can present as something as simple as just being slightly confused or altered, leading into progressively more severe elements such as word-finding difficulties, tremors, or changes in handwriting. Or even more severe cases that lead to seizures or decreased levels of consciousness. So, in this setting, neurologic assessments and knowing and understanding what your patient's baseline neurologic status is is so important. Those are really the two largest side effects that cross the board when it comes to CAR T therapies." TS 16:02 "In terms of the more practical aspects of administration, this is not a typical medication infusion. CAR T cells are living cells. So the way they are handled and administered is very specific. The majority of CAR T products are given as a single IV infusion. The cells come to us frozen either from a cellular lab or they will come from the pharmacy department. So those cells are typically thawed, and timing is of the essence. You really need to coordinate the timing of [thawing] to when they get infused to your patient. They tend to have a short shelf life once they're not frozen anymore." TS 26:34 "Now that therapy has, in many places, transitioned to be administered in the outpatient setting, education becomes absolutely critical. The patient is coming for their daily visit to clinic and then they're going home. And it's really up to the caregiver, who is usually not a nurse, who has to recognize early signs of toxicity. They need to be educated about what a fever is, what number constitutes a fever, what does confusion look like, what does hypotension look like? ... Do they have access to a thermometer? If you are asking them to look at blood pressure, do they have access to a blood pressure monitor? And sometimes those can be subtle things that might be overlooked. So, the emphasis in outpatient quality education is teaching those caregivers what to watch for, how to act quickly, and who to call immediately. You need to make sure that they have that information readily available if something happens." TS 30:55

learning body guide food new jersey patients iv commission earn kevin macleod rn cart msn stardust learners ts drug administration attribution ons pharmd pharmacology accreditation immunotherapy transplantation crs bcps car t cell therapy cancer immunotherapy car t cell hackensack university medical center bcop ncpd iraes oncologic emergencies john theurer cancer center

mRNA-based CAR T cell engineering with Norman Drzeniek and Niklas Kotzian

ASGCT Podcast Network

Play Episode Listen Later Mar 5, 2026 32:36

Dr. Marcin Kortylewski (Oligonucleotide therapies and applications Section Editor of Molecular Therapy Nucleic Acids) sits down with Dr. Norman Michael Drzeniek and Niklas Kotzian from the Berlin Institute of Health at Charité. Join them as they discuss their new article, mRNA-based CAR T cell engineering: Unmodified mRNA enables high CAR expression without innate immune activation in T cells. Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

health engineering car cart mrna niklas charit scott buckley car t cell section editor

Beyond Chemotherapy in ALL: Emerging Bispecific Antibodies, CAR T-cell Therapies, and Evolving Treatment Strategies

CCO Oncology Podcast

Play Episode Listen Later Feb 27, 2026 38:32

In this episode, Dr Ibrahim Aldoss and Dr Bijal Shah discuss how immunotherapy has transformed the treatment landscape of acute lymphoblastic leukemia (ALL), particularly in relapsed/refractory B-cell ALL, including: CD19-directed CAR T-cell therapies Next-generation CD19 bispecific antibodies The evolving role of allogeneic transplant Presenters: Ibrahim Aldoss, MD Associate Professor Division of Leukemia Department of Hematology/HCT City of Hope National Medical Center Duarte, California Bijal Shah, MD, MS Senior Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, Florida Link to full program: https://bit.ly/4cRjiUi Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

สภากาแฟ : CAR-T-CELL ความหวังของการรักษามะเร็งเมเลือดขาว_นพ.ภณรัตน์ น้อยเพิ่ม_พญ.อุมาพร แหยมอุบล

PSU Radio Podcast

Play Episode Listen Later Feb 16, 2026 58:19

สภากาแฟ : CAR-T-CELL ความหวังของการรักษามะเร็งเมเลือดขาว_นพ.ภณรัตน์ น้อยเพิ่ม_พญ.อุมาพร แหยมอุบล by PSU Broadcast FM88 MHz

car t cell

{Best of 2025} BMT & CAR T-Cell Updates: What You Need to Know for Your Patients

TheOncoPT Podcast

Play Episode Listen Later Dec 23, 2025 58:38

Send us a textTheOncoPT Podcast officially turned SEVEN, y'all! And a beautiful part of being around this long means that it's time for some knowledge updates:Bone Marrow Transplant (BMT) and CAR T-cell therapy are evolving fast—are you keeping up? In this episode of TheOncoPT Podcast, Dr. Adam Matichak returns to share the latest updates on these groundbreaking treatments and what they mean for your OncoPT practice.You'll learn how CAR T-cell therapy is expanding, why mobility strategies matter more than ever, and how to use vital signs to guide your treatment decisions. Plus, we'll explore how you can advocate for rehab's role in oncology, prepare patients for complex treatments like BMT and CAR T, and find the resources you need to stay ahead in this rapidly changing field.Whether you're new to cancer rehab or a seasoned pro, this conversation will give you practical tools to treat your patients undergoing BMT and/or CAR T-cell therapy. Listen now!Follow TheOncoPT on Instagram.Follow TheOncoPT on LinkedIn.

patients cart bmt car t cell

WSR091-CAR T-Cell Targeting oder der Todeskuss der Serienkiller - Interview mit Dr. Markus Barden

Wirkstoffradio (MP3 Feed)

Play Episode Listen Later Nov 30, 2025 80:28

In dieser Episode spricht Bernd Rupp mit Dr. Markus Barden über CAR-T-Zellen bzw. TRUCKs der 4. Generation. Markus erklärt Funktionsweise, Weiterentwicklung und wie neue Konstrukte vom Labor in die Klinik zur Behandlung solider Tumore gelangen.

generation labor trucks targeting weiterentwicklung behandlung klinik funktionsweise barden serienkiller tumore konstrukte car t cell

Episode 425: The ECTRIMS 2025 Deep Dive with Dr. Bruce Bebo

RealTalk MS

Play Episode Listen Later Oct 20, 2025 33:58

Just about a month ago, 9,600 researchers, clinicians, and representatives from patient advocacy organizations gathered in Barcelona for the European Committee on Treatment and Research in MS annual scientific congress, better known as ECTRIMS, the largest MS research conference in the world. Now that he's had an opportunity to review his notes and digest all of the science presented at ECTRIMS 2025, Dr. Bruce Bebo, the National MS Society's Executive Vice-President of Research, returns to the podcast to take us on a deep dive covering some of the most important research presented this year. We're also talking about next-generation CAR T-cell therapy for MS, and we'll explain why it's such exciting news. We're sharing details about a DNA-based therapy for overactive bladder that just received fast-track status from the FDA. We'll tell you about a new effort to develop a simple blood test that will detect MS progression. We have some news to share about the RealTalk MS app. And we want to remind you to check out our ECTRIMS Extra Conversations video playlist on the RealTalk MS YouTube channel! We have a lot to talk about! Are you ready for RealTalk MS??! This Week: A deep dive into the research presented at ECTRIMS 2025 :22 Kernal Biologics received $48 million grant for the next-generation CAR T-Cell therapy 2:35 FDA grants fast track designation to DNA-based therapy to treat overactive bladder 6:02 Octave Bioscience receives grant to develop a blood test to detect MS progression 8:30 News about our app 9:42 Have you checked out our ECTRIMS Extra Conversations YouTube playlist? 10:30 Dr. Bruce Bebo discusses some of the most important research presented at ECTRIMS 2025 11:06 Share this episode 32:26 Next week's episode 32:47 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/425 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com PARTICIPATE: Take the Shaping Tomorrow Together Survey https://s.alchemer.com/s3/Perspectives-on-MS REGISTER: Attend the virtual Shaping Tomorrow Together meeting with the FDA https://nmss.quorum.us/event/25463 SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy LISTEN: RealTalk MS Ep 422: From ECTRIMS 2025 with Dr. Bruce Bebo and Kristine Werner Ozug https://realtalkms.com/422 WATCH: The RealTalk MS ECTRIMS Extra Conversations video playlist on YouTube https://realtalkms.com/ectrims2025 JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms DOWNLOAD: The RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 DOWNLOAD: The RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 425 Guests: Dr. Bruce Bebo Privacy Policy

news research ms dna phone deep dive barcelona treatments perspectives fda activist cart bebo national ms society car t cell ios devices european committee ectrims realtalk ms

S2 Episode 3: When Is the Best Time to Use CAR T-Cell Therapy in Multiple Myeloma?

Medscape InDiscussion: Multiple Myeloma

Play Episode Listen Later Sep 23, 2025 24:38

Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002715. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Myeloma https://emedicine.medscape.com/article/204369-overview CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.8009 Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/37272512/ Plain Language Summary of the KarMMa-3 Study of Ide-cel or Standard of Care Regimens in People With Relapsed or Refractory Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/38651976/ CAR T-Cell Therapy Toxicity https://www.ncbi.nlm.nih.gov/books/NBK592426/ Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience https://pubmed.ncbi.nlm.nih.gov/28205024/ Incidence and Outcomes of Cytomegalovirus Reactivation After Chimeric Antigen Receptor T-Cell Therapy https://pubmed.ncbi.nlm.nih.gov/38838226/ Long-Acting Granulocyte Colony-Stimulating Factor in Primary Prophylaxis of Early Infection in Patients With Newly Diagnosed Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/35064823/ Revisiting the Role of Alkylating Agents in Multiple Myeloma: Up-to-Date Evidence and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/37244325/ Bispecific Antibodies for the Treatment of Relapsed/Refractory Multiple Myeloma: Updates and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/38660139/ FDA Eliminates REMS for Approved CAR T-Cell Therapies https://www.aabb.org/news-resources/news/article/2025/06/30/fda-eliminates-rems-for-approved-car-t-cell-therapies

action study md treatments relevant outcomes patel msc best time ide incidence multiple myeloma medscape car t cell therapy clinical experience car t cell jco

México se prepara para aplicar terapia con células CAR T-Cell

Noticentro

Play Episode Listen Later Aug 7, 2025 1:39

“El poder se ejerce con humildad”, afirma Sheinbaum Lluvias colapsan puente en Veracruz; afectan a ocho comunidadesEl café no da energía, sólo oculta el cansancio: expertosMás información en nuestro podcast

car xico terapia prepara veracruz aplicar sheinbaum car t cell

Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access

Project Oncology®

Play Episode Listen Later Aug 4, 2025

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center.

university safety patients myths associate professor realities debunking selection cart pharmd rmd bcps nebraska medical center hematology oncology car t cell reachmd oncology and hematology global oncology academy charles turck host charles turck

Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access

Project Oncology®

Play Episode Listen Later Aug 4, 2025

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center.

university safety patients myths associate professor realities debunking selection cart pharmd rmd bcps nebraska medical center hematology oncology car t cell reachmd oncology and hematology global oncology academy charles turck host charles turck

MPR Weekly Dose Podcast #240 — Wristband to Improve Tremors; Weight Loss Risk With ADHD Meds; REMS Eliminated for CAR T-Cell Immunotherapies; Zegfrovy Approved; New CDC Advisory Committee Has First Meeting

MPR Weekly Dose

Play Episode Listen Later Jul 4, 2025 14:09

Wristband that provides relief for upper limb tremor is approved; FDA warns of clinically significant weight loss in younger kids taking ADHD meds; REMS removed for CAR T-cell immunotherapies; treatment approved for lung cancer patients with EGFR exon20 insertion mutations; and CDC committee recommends removing preservative from flu vaccines.

medicine risk adhd weight loss cdc fda cart approved pharma meds tremors eliminated pharmaceuticals advisory committees immunotherapy first meeting egfr wristbands rems weekly dose car t cell thimerosal cdc advisory committee

Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access

Project Oncology®

Play Episode Listen Later Jun 23, 2025

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center.

university safety patients myths associate professor realities debunking selection cart pharmd rmd bcps nebraska medical center hematology oncology car t cell reachmd oncology and hematology global oncology academy charles turck host charles turck

Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access

Project Oncology®

Play Episode Listen Later Jun 23, 2025

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center.

university safety patients myths associate professor realities debunking selection cart pharmd rmd bcps nebraska medical center hematology oncology car t cell reachmd oncology and hematology global oncology academy charles turck host charles turck

S13 Ep18: Conversations About BTK Inhibitors and CAR T-Cell Therapies Bridge Gaps in Leukemia and Lymphoma: With Alexey Danilov, MD, PhD

OncLive® On Air

Play Episode Listen Later Jun 19, 2025 19:58

In today's episode, we had the pleasure of speaking with Alexey Danilov, MD, PhD, about current challenges and emerging treatment approaches for the management of leukemia and lymphoma that were published in a manuscript based on proceedings from the inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference. Dr Danilov is the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, co-director of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. In our exclusive interview, Dr Danilov highlighted recent advances and controversies in the treatment of select patients with hematologic malignancies. He noted chemotherapy-free regimens that are shifting treatment paradigms in mantle cell lymphoma, preferred and emerging BTK inhibitors for the management of chronic lymphocytic leukemia, and the evolution of CD19-directed CAR T-cell therapies for diffuse large B-cell lymphoma. Dr Danilov concluded by taking a forward glance at future developments like BTK degraders and novel CAR T-cell therapy targets.

california conversations phd md bridge bridging gaps cart duarte leukemia therapies lymphoma md phd btk inhibitors hematology alexey car t cell cd19 danilov

CAR-T Cell Breakthrough Threatened by NIH Cuts: Medical Advances, Vitamin Warnings, and Health Misinformation

Ask Doctor Dawn

Play Episode Listen Later Jun 13, 2025 48:04

Broadcast from KSQD, Santa Cruz on 6-12-2025: Dr. Dawn opens with alarming news about NIH budget cuts devastating cancer research just as breakthrough CAR-T cell therapy shows promise for gastrointestinal cancers. This personalized immunotherapy extracts patients' T cells, engineers them to target specific cancer antigens, and makes them essentially immortal before reinfusion. While previously successful only for blood cancers like leukemia and lymphoma, researchers achieved tumor shrinkage in 25% of solid GI tumor patients. However, devastating layoffs forced removal of two patients from trials due to staff shortages and supply chain disruptions. Dr. Dawn emphasizes how pregnancy can worsen hidden cancers due to immune suppression, explaining why aggressive metastasized cancers often appear shortly after childbirth. Dr. Dawn takes a call from Bob about concerning forehead growths his dermatologist examined. She speculates they're likely seborrheic keratoses - benign, stuck-on appearing growths common in sun-exposed areas that look like crumpled brown paper "spit-wads". These aging-related changes are harmless and can even be picked off, though she warns against repeatedly traumatizing any skin area as this increases cancer risk through accumulated DNA damage. She explains how repetitive trauma in occupational settings creates statistically higher cancer risks, comparing it to filling a bingo card of cellular errors. She addresses an email about Joe Tippens' cancer cure protocol involving fenbendazole, an anti-parasitic drug. Dr. Dawn explains this viral social media phenomenon began when Tippens claimed his lung cancer was cured by fenbendazole, but he was simultaneously receiving Keytruda immunotherapy at MD Anderson. The story spread rapidly in South Korea, causing pharmacy shortages. Unvalidated internet health information can spread dangerously. Dr. Dawn compares it to old-fashioned medicine show scams. trend Dr. Dawn warns about a recent vitamin B6 toxicity misdiagnosis trend affecting her patients who were told they had dangerous levels of B6 despite lacking neuropathy symptoms. Accuracy requires fasting 12 hours before blood draws, otherwise creating false elevations from recent vitamin consumption. More critically, she alerts listeners about biotin(Vitamin B7) interference with laboratory tests using biotin-streptavidin techniques. High-dose biotin supplements are often used in hair and nail health growth formulas. This can falsely alter tests for thyroid hormones, vitamin D, sex hormones, cortisol and dangerously, troponin levels that diagnose heart attacks. This could lead to missed myocardial infarctions in emergency rooms, potentially causing fatal outcomes. Dr. Dawn takes a call from Richard seeking information about a previous radio program guest. She guides him to use on-line resources at ksqd.org to find program details, pivoting into praise for libraries as community centers offering far more than internet access. She emphasizes libraries provide serendipitous discovery that algorithms can't match, encouraging people to explore their local library systems for events, historical collections, and personal assistance from knowledgeable librarians eager to help visitors navigate both physical and digital resources. She discusses the concerning trend of giving melatonin to children, calling it "the Grinch that stole children's bedtime." While used prescription-only for severe developmental disorders in Denmark and EU countries, American children receive melatonin gummies regularly, with one in five preteens using it occasionally. Dr. Dawn explains melatonin is a hormone affecting pancreas, heart, fat tissue, and reproductive organs still developing in children. Supplemental doses create blood levels 10 times higher than natural peaks, representing an uncontrolled medical experiment on developing brains and bodies. Poison control calls for melatonin ingestion increased 530% between 2012-2021, with one tragic case involving a three-month-old death where 20 melatonin bottles were found in the home. Dr. Dawn concludes by debunking food expiration date myths, explaining that Americans waste a third of food ($7 billion annually) due to misunderstanding labels. Most shelf-stable foods simply degrade in quality rather than becoming dangerous after printed dates. She notes acidic dairy products like yogurt resist bacterial contamination due to protective bacteria,and even surface mold can be scraped off safely. However, she emphasizes trusting expiration dates on lunch meats and deli products, which pose real listeria risks when stored improperly. California will soon simplify labeling laws to reduce confusion between quality and safety dates.

CAR-T Cell Breakthrough Threatened by NIH Cuts: Medical Advances, Vitamin Warnings, and Health Misinformation

Ask Doctor Dawn

Play Episode Listen Later Jun 13, 2025 48:04

Broadcast from KSQD, Santa Cruz on 6-12-2025: Dr. Dawn opens with alarming news about NIH budget cuts devastating cancer research just as breakthrough CAR-T cell therapy shows promise for gastrointestinal cancers. This personalized immunotherapy extracts patients' T cells, engineers them to target specific cancer antigens, and makes them essentially immortal before reinfusion. While previously successful only for blood cancers like leukemia and lymphoma, researchers achieved tumor shrinkage in 25% of solid GI tumor patients. However, devastating layoffs forced removal of two patients from trials due to staff shortages and supply chain disruptions. Dr. Dawn emphasizes how pregnancy can worsen hidden cancers due to immune suppression, explaining why aggressive metastasized cancers often appear shortly after childbirth. Dr. Dawn takes a call from Bob about concerning forehead growths his dermatologist examined. She speculates they're likely seborrheic keratoses - benign, stuck-on appearing growths common in sun-exposed areas that look like crumpled brown paper "spit-wads". These aging-related changes are harmless and can even be picked off, though she warns against repeatedly traumatizing any skin area as this increases cancer risk through accumulated DNA damage. She explains how repetitive trauma in occupational settings creates statistically higher cancer risks, comparing it to filling a bingo card of cellular errors. She addresses an email about Joe Tippens' cancer cure protocol involving fenbendazole, an anti-parasitic drug. Dr. Dawn explains this viral social media phenomenon began when Tippens claimed his lung cancer was cured by fenbendazole, but he was simultaneously receiving Keytruda immunotherapy at MD Anderson. The story spread rapidly in South Korea, causing pharmacy shortages. Unvalidated internet health information can spread dangerously. Dr. Dawn compares it to old-fashioned medicine show scams. trend Dr. Dawn warns about a recent vitamin B6 toxicity misdiagnosis trend affecting her patients who were told they had dangerous levels of B6 despite lacking neuropathy symptoms. Accuracy requires fasting 12 hours before blood draws, otherwise creating false elevations from recent vitamin consumption. More critically, she alerts listeners about biotin(Vitamin B7) interference with laboratory tests using biotin-streptavidin techniques. High-dose biotin supplements are often used in hair and nail health growth formulas. This can falsely alter tests for thyroid hormones, vitamin D, sex hormones, cortisol and dangerously, troponin levels that diagnose heart attacks. This could lead to missed myocardial infarctions in emergency rooms, potentially causing fatal outcomes. Dr. Dawn takes a call from Richard seeking information about a previous radio program guest. She guides him to use on-line resources at ksqd.org to find program details, pivoting into praise for libraries as community centers offering far more than internet access. She emphasizes libraries provide serendipitous discovery that algorithms can't match, encouraging people to explore their local library systems for events, historical collections, and personal assistance from knowledgeable librarians eager to help visitors navigate both physical and digital resources. She discusses the concerning trend of giving melatonin to children, calling it "the Grinch that stole children's bedtime." While used prescription-only for severe developmental disorders in Denmark and EU countries, American children receive melatonin gummies regularly, with one in five preteens using it occasionally. Dr. Dawn explains melatonin is a hormone affecting pancreas, heart, fat tissue, and reproductive organs still developing in children. Supplemental doses create blood levels 10 times higher than natural peaks, representing an uncontrolled medical experiment on developing brains and bodies. Poison control calls for melatonin ingestion increased 530% between 2012-2021, with one tragic case involving a three-month-old death where 20 melatonin bottles were found in the home. Dr. Dawn concludes by debunking food expiration date myths, explaining that Americans waste a third of food ($7 billion annually) due to misunderstanding labels. Most shelf-stable foods simply degrade in quality rather than becoming dangerous after printed dates. She notes acidic dairy products like yogurt resist bacterial contamination due to protective bacteria,and even surface mold can be scraped off safely. However, she emphasizes trusting expiration dates on lunch meats and deli products, which pose real listeria risks when stored improperly. California will soon simplify labeling laws to reduce confusion between quality and safety dates.

Updates on CAR T-cell Therapies

Chronic Myelogenous Leukemia CancerCare Connect Education Workshops

Play Episode Listen Later Mar 25, 2025 53:09

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts